ZZZhongsong Zhang

Zhongsong Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhongsong Zhang has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: nano-engineered precision strategies for hematological malignancies: current advances and translational roadmap

    by Zhongsong Zhang, Junhao Chen, Qi Shi, Zihan Zhou, Bing Wang, Panpan Gu, Junxian Zhao, Jiacheng Dai, Qian Sun, Yuanyin Teng

  • Open Access

    Multimodal nanomedicine for precision colorectal cancer management: integrated diagnosis, targeted therapy, and personalized theranostics

    by Keyi Gou, Zhongsong Zhang, Jingfeng Zhou, Fayun Zhou, Sixiang Yi, Xinrui Zhu, Zihao Zhao, Yuanyin Teng, Junhao Chen, Bing Wang, et al.

  • Open Access

    Engineering Multimodal Nanomaterials for Prostate Cancer Theranostics: Design Principles, Recent Advances, and Translational Challenges

    by Jia Wang, Zhongsong Zhang, Haihao Li, Yuanyin Teng, Bo Chen, Jieming Zuo, Xiangyun Li, Peiqin Zhan, Shi Fu, Yongqiang Xu, et al.

    Prostate cancer (PCa) remains a major clinical challenge because of limitations in early detection, tumor heterogeneity, therapeutic resistance, and metastatic progression. Nanomaterials provide versatile platforms for PCa theranostics by integrating molecular imaging, biomarker detection, targeted delivery, multimodal therapy, and therapeutic response assessment. This review summarizes recent advances in major nanomaterial platforms for PCa theranostics, including lipid-based nanomaterials, polymeric nanoparticles, gold nanoparticles (AuNPs), magnetic nanoparticles (MNPs), biomimetic nanoplatforms, and emerging smart nanocarriers, with emphasis on imaging enhancement, biosensing and liquid biopsy, targeted drug and nucleic acid delivery, phototherapy, sonodynamic and chemodynamic therapy (CDT), immunotherapy, and multimodal combination strategies. These advances reflect a shift from conventional single-function nanocarriers toward engineered multimodal theranostic systems that integrate molecular targeting, stimulus-responsive release, image-guided intervention, combination therapy, and therapeutic response monitoring. Unlike previous reviews that mainly describe nanomaterial categories or isolated applications, this review adopts an engineering-oriented design–function–application–translation framework to clarify how material properties, targeting strategies, and stimulus-responsive designs influence diagnostic performance, therapeutic selectivity, and clinical feasibility. Particular emphasis is placed on prostate-specific membrane antigen (PSMA)-targeted nanoplatforms as representative systems for theranostic integration. Current evidence suggests that nanoplatforms can improve tumor-selective accumulation, imaging sensitivity, biomarker detection, cargo stability, and intracellular delivery while reducing off-target toxicity. However, clinical translation remains limited by heterogeneous biodistribution, protein corona effects, nonspecific uptake, insufficient long-term biosafety data, manufacturing complexity, and batch-to-batch variability. Overall, nanomedicine may support more precise, minimally invasive, and integrated PCa management, but successful translation will require standardized characterization, scalable manufacturing, rigorous safety evaluation, clinically relevant validation, and rational integration with established diagnostic and therapeutic pathways.

  • Open Access

    Cancer-Associated Fibroblast-Targeted Nanomedicine in Solid Tumor Therapy: From Mechanisms of Therapeutic Resistance to Precision Stromal Modulation

    by Rong Wang, Zhongsong Zhang, Jiahui Du, Junhao Chen, Yuanyin Teng, Qi Wang, Zhu Wu, Ting Yang, Haiyan Jiang

    Solid tumors remain difficult to treat because their therapeutic resistance is shaped not only by malignant-cell heterogeneity but also by stromal barriers that prevent therapeutic agents and immune cells from effectively reaching and eliminating tumor cells. Among these stromal components, cancer-associated fibroblasts (CAFs) are among the most abundant and functionally influential cell populations in the tumor microenvironment. Through extracellular matrix remodeling, paracrine signaling, immune regulation, and metabolic crosstalk, CAFs profoundly influence therapeutic response and prognosis in solid tumors. As central stromal regulators, CAFs determine whether antitumor therapies can achieve effective tumor inhibition. This central regulatory role makes CAFs rational and increasingly important therapeutic targets in solid tumors. However, CAF-targeted therapy is complicated by the pronounced heterogeneity and plasticity of CAF populations. Distinct CAF subsets may exert divergent, or even opposing, effects on tumor progression and therapeutic response. Therefore, effective CAF-targeted therapy should move beyond nonspecific CAF depletion and instead focus on precise stromal modulation. Nanomedicine provides a powerful strategy to strengthen CAF-directed therapy because nanomaterials can be engineered to match the biological and spatial features of CAF-rich tumor stroma. By tuning size, charge, shape, porosity, surface ligands, biomimetic coatings, and stimulus-responsive release, nanocarriers can enhance stromal accumulation, bind CAF-associated targets, and convert CAF biology into actionable therapeutic selectivity. In this review, we summarize the biological origins, activation mechanisms, subtype heterogeneity, dual functions, and biomarker landscape of CAFs in solid tumors, and systematically discuss how CAFs drive therapeutic resistance through physical, biochemical, metabolic, and immune barriers. We then highlight current CAF-targeted nanomedicine strategies, including CAF-selective delivery, extracellular matrix remodeling, CAF reprogramming, immune microenvironment regulation, and combination with chemotherapy, radiotherapy, photothermal/photodynamic therapy, immune checkpoint blockade, and adoptive cell therapy. Finally, we discuss key translational challenges, including target specificity, deep stromal penetration, long-term safety, biomarker-guided patient stratification, scalable manufacturing, and AI-assisted nanocarrier optimization. Overall, CAF-targeted nanomedicine offers a promising route to transform the tumor stroma from a barrier to therapy into a modifiable therapeutic interface, thereby improving the precision and efficacy of solid tumor treatment.


  • Open Access

    Nanomedicine for Depression: From Blood–Brain Barrier Delivery to Neuroimmune–Barrier–Plasticity Network Reprogramming

    by Xiong Wang, Liping Shen, Qiang Mo, Xiaofei Wang, Bing Wang, Junhao Chen, Yuanyin Teng, Zhongsong Zhang

    Depression is a heterogeneous and recurrent brain disorder in which neuroinflammation, blood–brain barrier dysfunction, oxidative and mitochondrial stress, and impaired neuroplasticity interact within the neurovascular–glial–neuronal unit. This mechanism-oriented integrative review examines how engineered nanosystems may move beyond brain entry toward lesion-directed modulation of the neuroinflammation–barrier–neuroplasticity axis. We first synthesize the pathological nodes that sustain depression-related network dysfunction and then classify current nanotherapeutic strategies into three categories: small-molecule nanodelivery systems, nucleic acid nanocarriers, and functional nanoplatforms, including lipid and polymeric nanoparticles, inorganic and nanozyme-based systems, biomimetic membrane-coated nanoparticles, and engineered extracellular vesicles, including exosomes. Unlike previous nanosynthesis-focused or catalogue-style nanocarrier reviews, this review organizes the field around a disease-mechanism framework rather than material type alone, emphasizing barrier-state navigation, glial–neuronal–subcellular targeting, stimulus-responsive release, and coordinated modulation of inflammation, vascular integrity, redox homeostasis, and synaptic plasticity. We further argue that nanoplatforms should be evaluated not only by brain accumulation but also by patient stratification, engagement of defined pathological nodes, multimodal biomarker evidence of network-level modulation, manufacturability, and safety under repeated administration. Major translational bottlenecks include insufficient subtype-specific patient selection, limited human relevance of current stress- and inflammation-based models, uncertain biodistribution and long-term neurotoxicity, constraints in scaling up nose-to-brain delivery, batch-to-batch variability, cargo instability, immunogenicity, and unclear regulatory classification of complex biologic or combination products. Finally, we propose a pathological-network-guided precision nanomedicine framework that integrates blood–brain barrier status assessment, liquid biopsy and imaging biomarkers, human-relevant validation models, and scalable quality control to guide future platform design and clinical translation. This review provides a disease-mechanism-centered roadmap for transforming nanomedicine for depression from delivery optimization into precision network-oriented intervention.


  • Open Access

    Extracellular Vesicle-Associated Non-Coding RNAs in Preeclampsia: Mechanistic Insights, Biomarker Discovery, and Emerging Nanomedicine Concepts

    by Zhongsong Zhang, Jiahui Du, Tianze Chen, Yuanyin Teng, Junhao Chen, Yanpei Li, Yang Zhang, Yingfei Long, Chanyu Li, Zhu Wu, et al.

    Preeclampsia (PE) is a complex multisystem disorder that affects 2– 8% of pregnancies worldwide and poses substantial risks to maternal and fetal health. Current diagnostic approaches rely largely on clinical signs and angiogenic biomarkers, and available treatments remain primarily supportive; they do not directly reverse the placental or systemic mechanisms that drive the disease. Extracellular vesicles (EVs), including small EVs often termed exosomes, carry non-coding RNAs (ncRNAs) that may contribute to placental–maternal communication in both normal and pathological pregnancy. In PE, altered EV-associated microRNAs, long non-coding RNAs, and circular RNAs have been detected in placental tissues, trophoblast-derived systems, maternal plasma or serum, urine, amniotic fluid, and other pregnancy-related samples. However, these matrices should not be assumed to indicate definitive tissue or cellular origins without appropriate source-attribution methods. This review summarizes current evidence on EV-associated ncRNAs in PE from three perspectives: mechanistic studies, biomarker discovery, and exploratory nanomedicine strategies. First, we discuss how dysregulated EV-associated ncRNAs may contribute to trophoblast dysfunction, immune-inflammatory imbalance, endothelial injury, and angiogenic dysregulation. Second, we evaluate EV-associated ncRNAs as candidate liquid-biopsy biomarkers, emphasizing that most reported signatures remain at the discovery or early validation stage. Their clinical implementation will require standardized EV isolation, RNA profiling, normalization procedures, and validation in independent longitudinal cohorts. Third, we discuss engineered EVs and EV-mimetic nanocarriers as experimental platforms for ncRNA delivery and distinguish these preclinical therapeutic concepts from clinically established PE management. Rather than suggesting immediate diagnostic or therapeutic readiness, this review highlights the opportunities and limitations of EV-associated ncRNAs as a framework for future PE research. Key challenges include EV heterogeneity, limited discrimination among vesicular subtypes, uncertain tissue origins of circulating EV cargo, poor reproducibility across cohorts, safety concerns during pregnancy, scalable manufacturing, and ethical considerations related to maternal–fetal interventions. Future studies integrating rigorously characterized EV populations, multi-omics profiling, functional validation, and longitudinal clinical sampling are essential to determine whether EV-associated ncRNAs can be translated into reliable PE biomarkers or safe nanomedicine-based interventions.

  • Open Access

    The Application of Nanomaterials in Kidney Stone Disease: Emerging Strategies for Early Diagnosis, Targeted Therapy, and Prevention

    by Jieming Zuo, Zhongsong Zhang, Junhao Chen, Keyi Gou, Jingfeng Zhou, Lingxiang Wen, Hairong Wei, Xiangyun Li, Peiqin Zhan, Peng Chen, et al.

    Kidney stone disease is one of the most common urologic disorders worldwide and imposes a growing clinical and socioeconomic burden because of its rising prevalence, high recurrence rate, and association with chronic kidney injury and systemic metabolic abnormalities. Calcium oxalate (CaOx) stones remain the predominant stone type, and their formation is now recognized as a multistep process involving urinary supersaturation, crystal nucleation and growth, tubular epithelial injury, oxidative stress, inflammation, and crystal retention. Although current management strategies, including dietary modification, pharmacologic prevention, and endourologic interventions, have substantially improved stone clearance, important limitations remain. These include inadequate early detection, suboptimal prevention of recurrence, insufficient targeting of the local renal microenvironment, and procedure-related complications. Recent advances in nanotechnology offer new opportunities to address these unmet needs. Owing to their large specific surface area, tunable physicochemical properties, versatile surface functionalization, and capacity for multimodal integration, nanomaterials have shown considerable promise in metabolic sensing, urinary biomarker detection, targeted drug delivery, modulation of crystal growth, biomimetic renal targeting, and photothermal or photoresponsive lithotripsy. In parallel, the convergence of nanotechnology with artificial intelligence, smart diagnostic devices, and personalized metabolic profiling is reshaping kidney stone management. This shift is moving the field from passive stone removal toward active risk prediction, dynamic monitoring, and precision prevention. In this review, we summarize recent advances in nanomaterial-based strategies for the diagnosis, treatment, and prevention of kidney stones, with particular emphasis on CaOx disease. We also discuss the major translational barriers, including biocompatibility, long-term safety, regulatory complexity, scalable manufacturing, and cost-effectiveness, and outline future directions for clinically integrated, intelligent, and individualized stone care.

  • Open Access

    Nanomaterials targeting cancer-associated fibroblasts to overcome stromal barriers in cancer immunotherapy

    by Zhongsong Zhang, Rong Wang, Long Chen

    Cancer-associated fibroblasts (CAFs) play a pivotal role in the tumor microenvironment (TME), influencing tumor progression, immune evasion, metastasis, and resistance to therapy. In parallel, emerging evidence underscores the therapeutic potential of targeting CAFs in cancer treatment. While CAFs exhibit significant heterogeneity, with different subtypes contributing to various aspects of tumor biology, including ECM remodeling, immune modulation, and cancer cell proliferation. This complexity presents a challenge in targeting CAFs for effective cancer therapy. Recent advancements in nanotechnology have offered novel strategies for precisely targeting CAFs, thereby modulating the TME to enhance the efficacy of cancer immunotherapy. This review provides a comprehensive overview of CAF biology, the mechanisms through which CAFs contribute to immune suppression and therapy resistance, and the emerging role of CAF-targeted nanomedicines in overcoming these barriers. Key strategies discussed include CAF reprogramming, ECM barrier disruption, and the targeting of immune checkpoints, all aimed at reshaping the TME into a more immune-permissive environment. However, despite promising preclinical results, several challenges remain, such as optimizing nanoparticle delivery, overcoming CAF-related drug resistance, and addressing the complex immunosuppressive networks within the TME. Future research should focus on the development of more targeted and personalized nanomedicine approaches, improving CAF-specific drug delivery systems, and better understanding the dynamic interactions between CAFs and the immune system. Our review highlights the current advances in CAF-targeted nanomedicine and underscores the importance of these strategies in advancing cancer immunotherapy. Ultimately, overcoming the challenges associated with CAF-targeted therapies could significantly improve clinical outcomes and pave the way for more effective, individualized cancer treatments.


  • Open Access

    Nano-engineered precision strategies for hematological malignancies: current advances and translational roadmap

    by Zhongsong Zhang, Junhao Chen, Qi Shi, Zihan Zhou, Bing Wang, Panpan Gu, Junxian Zhao, Jiacheng Dai, Qian Sun, Yuanyin Teng